Background And Objective: Prostate cancer is the most common cancer of the male reproductive system. With the development of medical imaging technology, magnetic resonance images (MRI) have been used in the diagnosis and treatment of prostate cancer because of its clarity and non-invasiveness. Prostate MRI segmentation and diagnosis experience problems such as low tissue boundary contrast. The traditional segmentation method of manually drawing the contour boundary of the tissue cannot meet the clinical real-time requirements. How to quickly and accurately segment the prostate tumor has become an important research topic.

Methods: This paper proposes a prostate tumor diagnosis based on the deep learning network PSP-Net+VGG16. The deep convolutional neural network segmentation method based on the PSP-Net constructs a atrous convolution residual structure model extraction network. First, the three-dimensional prostate MRI is converted to two-dimensional image slices, and then the slice input of the two-dimensional image is trained based on the PSP-Net neural network; and the VGG16 network is used to analyze the region of interest and classify prostate cancer and normal prostate.

Results: According to the experimental results, the segmentation method based on the deep learning network PSP-Net is used to identify the data set samples. The segmentation accuracy is close to the Dice similarity coefficient and Hausdorff distance, and even exceeds the traditional prostate image segmentation method. The Dice index reached 91.3%, and the technique is superior in speed of processing. The predicted tumor markers are very close to the actual markers manually by clinicians; the classification accuracy and recognition rates of prostate MRI based on VGG16 are as high as 87.95% and 87.33%, and the accuracy rate and recall rate of the network model are relatively balanced. The area under curve index is also higher than other models, with good generalization ability.

Conclusion: Experiments show that prostate cancer diagnosis based on the deep learning network PSP-Net+VGG16 is superior in accuracy and processing time compared to other algorithms, and can be well applied to clinical prostate tumor diagnosis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmpb.2022.106770DOI Listing

Publication Analysis

Top Keywords

prostate tumor
16
deep learning
16
learning network
16
prostate cancer
16
segmentation method
16
prostate
12
prostate mri
12
based deep
12
network
9
psp-net+vgg16 deep
8

Similar Publications

CXCL14 is a highly conserved chemokine expressed in various cell types, playing crucial roles in both physiological and pathological processes, including immune regulation and tumorigenesis. Recently, the role of CXCL14 in tumors has attracted considerable attention. However, previous pan-cancer studies have reported inconsistencies regarding the effects of CXCL14 on tumors, particularly concerning its expression levels in tumor tissues and its influence on various phenotypes of cancer cells.

View Article and Find Full Text PDF

Prognostic Value of Response Evaluation Using PSMA PET/CT in Patients with Metastatic Prostate Cancer (RECIP 1.0): A Systematic Review and Meta-analysis.

Acad Radiol

January 2025

University Medical Imaging Toronto, Joint Department of Medical Imaging, University Health Network-Sinai Health System -Women's College Hospital, University of Toronto, Toronto, ON, Canada (S.A.M., P.V.H., U.M., A.B.D.). Electronic address:

Rationale And Objectives: Recently, the Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) was proposed to better evaluate treatment response in prostate cancer patients using PET/CT with prostate-specific membrane antigen (PSMA) than more traditional approaches like metabolic PET evaluation response criteria in solid tumor (PERCIST 1.0).

View Article and Find Full Text PDF

Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer.

Trends Endocrinol Metab

January 2025

Department of Urology, Emory University School of Medicine, Atlanta, GA, USA; Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA. Electronic address:

Prostate cancer (PC) is a notoriously immune-cold tumor in that it often lacks substantial infiltration by antitumor immune cells, and in advanced diseases such as neuroendocrine PC, it could be devoid of immune cells. A majority of PC patients thus have, unfortunately, been unable to benefit from recent advances in immunotherapies. What causes this immunosuppressive microenvironment around PC? In this review, we discuss various genetic and epigenetic regulators intrinsic to prostate tumor cells that could have profound effects on the tumor microenvironment, thus contributing to this immune-cold status.

View Article and Find Full Text PDF

Radionuclides used for imaging and therapy can show high molecular specificity in the body with appropriate targeting ligands. We hypothesized that local energy delivered by molecularly targeted radionuclides could chemically activate prodrugs at disease sites while avoiding activation in off-target sites of toxicity. As proof of principle, we tested whether this strategy of radionuclide-induced drug engagement for release (RAiDER) could locally deliver combined radiation and chemotherapy to maximize tumor cytotoxicity while minimizing off-target exposure to activated chemotherapy.

View Article and Find Full Text PDF

High-volume disease (HVD) and low-volume disease (LVD) definitions in metastatic hormone-sensitive prostate cancer (mHSPC) patients are based on conventional imaging (CI) (CT/MRI with bone scan [BS]) according to CHAARTED criteria. HVD and LVD definitions are associated with overall survival and are used for treatment decisions. It remains unknown how these definitions transfer to prostate-specific membrane antigen (PSMA) PET imaging.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!